Lexeo CEO sells 3,345 shares to cover RSU taxes

Lexeo Therapeutics, Inc. (LXEO) reported that Chief Executive Officer and director Richard Nolan Townsend sold 3,345 shares of Common Stock on 2026-08-18.

Rhea-AI Filing Summary

Lexeo Therapeutics, Inc. (LXEO) reported that Chief Executive Officer and director Richard Nolan Townsend sold 3,345 shares of Common Stock on 2026-08-18. The sale, at a weighted average price of $4.9512 per share (individual trades ranged from $4.83 to $5.01), was to cover tax obligations on the release of restricted stock units (RSUs). Following this transaction, he directly holds 374,472 shares of Lexeo common stock, which includes 242,911 RSUs.

Insider Trade Summary

Net Seller: 3,345 shares

Net Sell 1 txn

Insider Townsend Richard Nolan

Role Chief Executive Officer

Sold 3,345 shs ($17K)

Type	Security	Shares	Price	Value
Sale	Common Stock F1, F2, F3	3,345	$4.9512	$17K

Holdings After Transaction: Common Stock — 374,472 shares (Direct)

Footnotes (3)

1. F1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").
2. F2. This transaction was executed in multiple trades at prices ranging from $4.83 to $5.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
3. F3. Includes 242,911 Restricted Stock Units.

Key Figures

Shares sold: 3,345 shares Weighted average sale price: $4.9512 per share Price range of trades: $4.83–$5.01 per share +2 more

5 metrics

Shares sold 3,345 shares Common Stock sold on 2026-08-18 to cover tax obligations on RSU release

Weighted average sale price $4.9512 per share Weighted average price for multiple trades executed between $4.83 and $5.01

Price range of trades $4.83–$5.01 per share Range of individual trade prices for the 3,345 shares sold

Shares owned after transaction 374,472 shares Directly owned Common Stock by CEO following the 2026-08-18 sale

Restricted Stock Units included 242,911 RSUs Number of RSUs included within the CEO’s post-transaction holdings

Key Terms

Restricted Stock Units, weighted average sale price, open market or private transaction

3 terms

Restricted Stock Units financial

"Includes 242,911 Restricted Stock Units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

weighted average sale price financial

"The price reported above reflects the weighted average sale price."

open market or private transaction financial

"Sale in open market or private transaction"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did LXEO report for CEO Richard Nolan Townsend?

Lexeo Therapeutics (LXEO) reported that CEO Richard Nolan Townsend sold 3,345 shares of Common Stock on 2026-08-18. The sale was to cover tax obligations arising from the release of restricted stock units, rather than a discretionary open-market reduction.

At what price did the LXEO CEO sell shares in this Form 4 filing?

The LXEO CEO’s reported sale used a weighted average price of $4.9512 per share. The transaction was executed in multiple trades at prices ranging from $4.83 to $5.01, all on 2026-08-18, as disclosed in the footnotes.

How many LXEO shares does the CEO hold after the reported sale?

After the transaction, the LXEO CEO directly holds 374,472 shares of Common Stock. This total includes 242,911 Restricted Stock Units (RSUs), which are share-based awards that may settle in stock as they vest over time.

Was the LXEO CEO’s August 18, 2026 share sale part of a 10b5-1 trading plan?

The filing indicates the Rule 10b5-1 checkbox is not marked as affirmatively used for this transaction. Instead, the sale is specifically described as to cover tax obligations on the release of restricted stock units, according to the footnote.

What is the nature of the LXEO CEO’s reported share sale on the Form 4?

The LXEO CEO’s reported sale represents shares sold to cover tax obligations related to the release of RSUs. This means a portion of the vested equity award was sold to satisfy tax liabilities, rather than as a purely discretionary portfolio transaction.

How many Restricted Stock Units does the LXEO CEO have included in his holdings?

The CEO’s post-transaction holdings of 374,472 shares include 242,911 Restricted Stock Units (RSUs). RSUs are contingent equity awards that typically convert into common stock upon meeting vesting or other specified conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/19/2026 - 05:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Townsend Richard Nolan

(Last) (First) (Middle)

C/O LEXEO THERAPEUTICS, INC.

345 PARK AVENUE SOUTH, FLOOR 6

(Street)

NEW YORK NEW YORK 10010

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lexeo Therapeutics, Inc. [ LXEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/18/2026		S(1)		3,345	D	$4.9512(2)	374,472(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a sale to cover tax obligations on the release of restricted stock units ("RSUs").

2. This transaction was executed in multiple trades at prices ranging from $4.83 to $5.01. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

3. Includes 242,911 Restricted Stock Units.

	/s/ Youjin Choi, Attorney-in-Fact	08/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)